---
authors:
- Bald, Elizabeth
- Raber, Hanna
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36689981/
file_path: 2023/01/semaglutide-wegovy-for-the-treatment-of-obesity.md
issue: '1'
keywords:
- Diabetes Mellitus, Type 2
- Obesity
- Humans
- Glucagon-Like Peptides
- Diabetes
- Hypoglycemic Agents
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Obesity
- Glucagon-Like Peptides
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
original_format: PubMed
pages: 90-91
patient_population: Adults
peer_reviewed: true
pmid: '36689981'
processed_date: '2025-07-30'
publication_date: '2023-01-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-07-30'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Semaglutide (Wegovy) for the Treatment of Obesity.
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '107'
---

# Semaglutide (Wegovy) for the Treatment of Obesity.

**Authors:** Bald, Elizabeth, Raber, Hanna

**Published in:** American family physician | Vol. 107, No. 1 | 2023-01-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36689981/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Obesity, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36689981/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
